The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.
Veracyte Inc (NASDAQ:VCYT)
- On July 30, Veracyte posted better-than-expected quarterly earnings. “Q2 was a milestone quarter for Veracyte as we launched two new products, Prosigna LDT and TrueMRD for MIBC, while also delivering strong double-digit revenue growth, profitability and cash generation,” said Marc Stapley, Veracyte’s chief executive officer. The company’s stock fell around 29% over the past month and has a 52-week low of $28.25.
- RSI Value: 28.8
- VCYT Price Action: Shares of Veracyte fell 3.3% to close at $40.68 on Tuesday.
- Edge Stock Ratings: 71.08 Momentum score with Value at 53.52.
Akso Health Group – ADR (NASDAQ:AHG)
- On April 27, Akso Health Group initiated an R&D program for its proprietary brain-computer interface technology. Yilin (Linda) Wang, Chief Executive Officer of Akso Health Group, said, “This strategic initiative marks the beginning of our effort to build a new, long-term growth engine for AHG. We are investing in the foundational R&D and intellectual property we believe will be necessary to compete in the global neurotechnology market. We are committed to pursuing it rigorously and in full compliance with all applicable regulations.” The company’s stock fell around 35% over the past month and has a 52-week low of $1.03.
- RSI Value: 28.7
- AHG Price Action: Shares of Akso Health fell 14.9% to close at $1.03 on Tuesday.
- Benzinga Pro’s charting tool helped identify the trend in AHG stock.
Inogen Inc (NASDAQ:INGN)
- On Aug. 6, Inogen posted downbeat quarterly sales. “Our second quarter results demonstrate continued demand for our products and validate the progress of our strategy to expand and diversify Inogen’s respiratory care portfolio,” said Kevin Smith, President and Chief Executive Officer. The company’s stock fell around 13% over the past month and has a 52-week low of $5.38.
- RSI Value: 28.3
- INGN Price Action: Shares of Inogen fell 1.9% to close at $5.60 on Tuesday.
- Benzinga Pro’s newsfeed feature notified of recent developments in INGN shares.
BZ Edge Rankings: Find out where other stocks stand—explore the full comparison now.
Photo via Shutterstock
Latest Private Market Opportunities
Market News and Data brought to you by Benzinga APIs
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.